SCHEMBL29890331

SCHEMBL29890331

COc1ccc(-c2cnn(C)c2)c2nc(NC(=O)N3CCC(C)(O)CC3)[nH]c12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 3/20 0.42
▸ ADORA1 P30542 3/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42
▸ ADORA2B P29275 1/20 0.42
▸ AAK1 Q2M2I8 1/20 0.38
▸ GSK3B P49841 4/20 0.37
▸ DYRK1A Q13627 4/20 0.37
▸ WNT1 P04628 1/20 0.37
▸ TTK P33981 4/20 0.36
▸ CCNA2 P20248 2/20 0.36
▸ CDK2 P24941 2/20 0.36
▸ MALT1 Q9UDY8 1/20 0.36
▸ USP30 Q70CQ3 1/20 0.35
▸ CSF1R P07333 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ PDGFRA P16234 1/20 0.35
▸ CCNT1 O60563 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ AXL P30530 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22183188 1.00 ADORA2A (0.42) ADORA2AADORA1ADORA3ADORA2BAAK1
SCHEMBL29889453 0.95 ADORA3 (0.38) ADORA2AADORA1ADORA3ADORA2BAAK1
SCHEMBL29889205 0.91 AAK1 (0.38) ADORA2AADORA1ADORA3ADORA2BAAK1
SCHEMBL20795852 0.91 AAK1 (0.38) ADORA2AADORA1ADORA3ADORA2BAAK1
SCHEMBL29889305 0.91 ADORA2A (0.44) ADORA2AADORA1ADORA3ADORA2BAAK1
SCHEMBL30014888 0.90 L3MBTL1 (0.42) ADORA2AADORA1AAK1GSK3BDYRK1A
SCHEMBL22183184 0.90 TTK (0.37) ADORA2AADORA1ADORA3ADORA2BAAK1
SCHEMBL22182977 0.90 AAK1 (0.38) ADORA2AADORA1ADORA3ADORA2BAAK1
SCHEMBL29889558 0.90 AAK1 (0.38) ADORA2AADORA1ADORA3ADORA2BAAK1
SCHEMBL29889254 0.90 TTK (0.37) ADORA2AADORA1ADORA3ADORA2BAAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3672952-B1 BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 — — EP claimed
EP-3672952-B1 BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 — — EP disclosed
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-09-29 — — US disclosed
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists MERCK PATENT GMBH (DE) 2022-09-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306588-A1 BEZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA1, ADORA2A, ADORA3 ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885
US-11453647-B2 Benzimidazole derivatives as adenosine receptor antagonists ADORA1, ADORA2A, ADORA3 ADORA2A 2/4885ADORA1 1/4885ADORA3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback